Impact of lanadelumab on patient-reported outcomes in hereditary angioedema in the US and Canada: Interim findings from the EMPOWER Study

Paula Busse,Rafael Zaragoza-Urdaz,Stephen Betschel,H. James Wedner,Emily Brouwer,Tomas Andriotti,Kezhen Fei,Michael Manning,Bruce Zuraw,Jonathan Bernstein

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY（2022）

引用 1|浏览8

暂无评分

摘要

Efficacy and safety of lanadelumab in patients with HAE-C1-INH were evaluated in phase 3 clinical trials (NCT02586805; NCT02741596). An objective of EMPOWER, an ongoing observational, real-world study, is to describe lanadelumab users’ patient-reported outcomes (PROs) over time.

查看译文

关键词

Hereditary Angioedema

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要